LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults

NCT07463365 | Not Yet Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: 25-1076
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This research study is investigating a new topical medication called LUT017, which is being developed to help heal chronic skin wounds, particularly those known as venous leg ulcers (VLUs). VLUs are open sores that commonly occur on the lower legs due to poor blood flow in the veins. These wounds can be painful, slow to heal, and difficult to treat, especially in older adults and people with conditions like diabetes or obesity. LUT017 is a gel that will be applied directly to the surface of these wounds. The goal of the study is to find out if the gel is safe and well tolerated when applied once a week for up to 8 weeks. The researchers will also look for early signs of whether the gel helps the wounds heal more quickly or completely. The gel contains a medicine that has been shown in animal studies to activate natural skin repair processes and promote cell growth, potentially speeding up the healing process. The study will involve between 12 and 18 adult participants who have had a chronic leg wound for at least 4 weeks. All participants will go through a screening process to make sure they are eligible. If they qualify, they will first complete a two-week "run-in" phase where their wound will be treated with standard medical bandages. This phase helps ensure that only participants whose wounds are not healing with normal care are included. If participants remain eligible after this period, they will start the treatment phase. During this phase, they will come to the clinic once a week for 8 weeks to receive the LUT017 gel treatment directly on their wound. Each visit will include a physical exam, vital signs, wound evaluation, photographs of the wound, and blood tests to monitor safety. After the 8-week treatment period, participants will return for two follow-up visits-one at 3 months and one at 6 months after their first treatment. These visits will help the researchers understand how long any benefits of the treatment might last and monitor for any delayed side effects. In total, participants will be involved in the study for about 6.5 months and will have approximately 12 to 14 visits to the clinic. Participation is entirely voluntary, and individuals can withdraw at any time. The research team is committed to ensuring participant safety and privacy throughout the study.

Conditions

Venous Leg Ulcer; Chronic Non-Healing Cutaneous Wounds; VLU

Keywords

Venous Leg Ulcer; Chronic Wound Healing; Topical BRAF Inhibitor; LUT017; Paradoxical MAPK Activation; Epidermal Regeneration; Cutaneous Wound Healing; Phase 1 Clinical Trial; Dose Escalation Study; Re-epithelialization; Dermatologic Regenerative Therapy; Local MAPK Activation

Outcome Measures

Primary Outcomes (1)

• Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

  Number and percentage of participants experiencing treatment-emergent adverse events (AEs), including adverse drug reactions (ADRs), serious adverse events (SAEs), unexpected adverse events, AEs leading to discontinuation, and AEs leading to death. Adverse events are graded according to CTCAE criteria and assessed for relationship to study drug.

  From first dose (Day 0) through Week 8 (end of treatment period)

Secondary Outcomes (3)

• Change in Wound Area Over Time

  Baseline through Week 8, Month 3, and Month 6

• Rate of Complete Re-epithelialization

  Week 8, Month 3, and Month 6

• Time to Complete Re-epithelialization

  From Day 0 through Month 6

Study Arms (3)

LUT017 Gel 0.03% Once Weekly

EXPERIMENTAL

Participants receive LUT017 gel 0.03% (0.3 mg/g) applied topically once weekly for up to 8 weeks to a designated chronic venous leg ulcer or non-healing cutaneous wound. Treatment is administered in clinic following a 14-day run-in period of standardized wound care. Safety, tolerability, pharmacokinetics, and wound healing parameters are evaluated throughout treatment and follow-up.

Drug: LUT017 gel

LUT017 Gel 0.1% Once Weekly

EXPERIMENTAL

Participants receive LUT017 gel 0.1% (1.0 mg/g) applied topically once weekly for up to 8 weeks to a designated chronic venous leg ulcer or non-healing cutaneous wound. Treatment is administered in clinic following a 14-day run-in period of standardized wound care. Dose escalation proceeds according to a 3+3 design based on observed safety.

Drug: LUT017 gel

LUT017 Gel 0.25% Once Weekly

EXPERIMENTAL

Participants receive LUT017 gel 0.25% (2.5 mg/g) applied topically once weekly for up to 8 weeks to a designated chronic venous leg ulcer or non-healing cutaneous wound. Enrollment in this cohort occurs after safety review of lower dose levels under the predefined dose-escalation rules.

Drug: LUT017 gel

Interventions

LUT017 gel DRUG

LUT017 gel is a topical formulation of a small-molecule BRAF inhibitor developed to induce paradoxical activation of the MAPK pathway in BRAF wild-type keratinocytes. The gel is administered once weekly for up to 8 weeks directly to a designated venous leg ulcer or chronic non-healing cutaneous wound. Three concentrations (0.03%, 0.1%, and 0.25% w/w) are evaluated sequentially using a 3+3 dose-escalation design. The formulation is an aqueous-based gel containing organic solvents to optimize dermal penetration while minimizing systemic absorption. Treatment is applied in clinic by qualified investigators following a 14-day run-in period of standardized wound care.

Also known as: LUT017, Topical BRAF inhibitor

LUT017 Gel 0.03% Once Weekly; LUT017 Gel 0.1% Once Weekly; LUT017 Gel 0.25% Once Weekly

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with venous leg ulcers (VLU), defined by open skin lesion of the leg as a result of venous hypertension.
• Subject must be ≥ 18 years of age.
• Active lower extremity ulceration (CEAP classification of C6).
• Non-healing VLU ≥ 4 weeks but not greater than 24 months.
• Ulcer size ≥ 2cm2 ≤ 20cm2.
• a. Target ulcer will be defined as the largest ulcer on the affected limb. Only one wound per subject will be designated as the study wound and treated with the investigational gel. If a subject has two wounds separated by less than 1 cm of intact skin, these wounds will be considered a single study wound, and the surface areas of both wounds will be added together for eligibility purposes; if the combined area exceeds 20 cm², the subject will be excluded from the study. Although only one wound will be directly treated, local activation of the MAPK pathway may result in biological stimulation of the adjacent untreated wound when wounds are separated by less than 1 cm.
• Chronic venous insufficiency confirmed by ultrasound within previous 12 months.
• Adequate perfusion confirmed within the past 12 months.:
• Dorsalis Pedis (DP) or Posterior Tibial (PT) systolic pressure ≥ 60mmHg on the study limb.
• Transcutaneous partial pressure oxygen (TcP02) \> 30mmHg.
• Great toe systolic pressure \> 40mmHg.
• Must be able and willing to provide informed consent prior to study participation.
• Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at baseline (Day 0). They should agree to use highly effective methods of birth control, defined as those with failure less than 1%, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUD's), sexual abstinence, or a vasectomized partner. Such subjects should agree to have monthly pregnancy test documented.

You may not qualify if:

• Target ulcer has exposed of tendon, muscle, or bone.
• Target ulcer is of non-venous etiology.
• Target ulcer has been treated with living cellular therapy within 4 weeks of the randomization.
• Target ulcer shows any signs of infection (only non-infected ulcers are eligible).
• Patient has undergone endovenous ablation or other venous surgery within 4 weeks of enrollment.
• Unable to tolerate multi-layer bandages or compression garments.
• Decompensated congestive heart failure within 4 weeks of screening.
• Active soft tissue or bone infection requiring antibiotics.
• Skin cancer on the target limb within the last 24 months.
• Actively receiving chemotherapy and/or radiation therapy for cancer.
• Treatment with a serine/threonine-protein kinase BRAF inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), BraftoviTM (encorafenib) or Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer.
• Blood chemistry or counts values as follows:
• White Blood Cells (WBC)\< 1.5 x 109/L.
• Absolute \< 0.9 x 109/L.
• Platelet count \< 50 x 109/L.

Sponsors & Collaborators

• Antoni Ribas: lead

Study Sites (1)

University of California, Los Angeles

Los Angeles, California, 90095, United States

Location

Related Publications (16)

• Zhu S, Li S, Escuin-Ordinas H, Dimatteo R, Xi W, Ribas A, Segura T. Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs. J Control Release. 2018 Jul 28;282:156-165. doi: 10.1016/j.jconrel.2018.05.006. Epub 2018 May 9.

  PMID: 29751029 BACKGROUND

• Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther. 2005 Apr;4(4):650-8. doi: 10.1158/1535-7163.MCT-04-0238.

  PMID: 15827339 BACKGROUND

• Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

  PMID: 22256804 BACKGROUND

• Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902.

  PMID: 20179705 BACKGROUND

• Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L, Leyden J. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005 May;10(5):345-56. doi: 10.1634/theoncologist.10-5-345.

  PMID: 15851793 BACKGROUND

• Pastore S, Mascia F, Mariotti F, Dattilo C, Mariani V, Girolomoni G. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol. 2005 Apr 15;174(8):5047-56. doi: 10.4049/jimmunol.174.8.5047.

  PMID: 15814736 BACKGROUND

• Nowak JA, Polak L, Pasolli HA, Fuchs E. Hair follicle stem cells are specified and function in early skin morphogenesis. Cell Stem Cell. 2008 Jul 3;3(1):33-43. doi: 10.1016/j.stem.2008.05.009.

  PMID: 18593557 BACKGROUND

• Mittmann N, Seung SJ. Rash rates with egfr inhibitors: meta-analysis. Curr Oncol. 2011 Apr;18(2):e54-63. doi: 10.3747/co.v18i2.605.

  PMID: 21505590 BACKGROUND

• Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Cancer Discov. 2021 Sep;11(9):2158-2167. doi: 10.1158/2159-8290.CD-20-1847. Epub 2021 Apr 28.

  PMID: 33910927 BACKGROUND

• Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006 Oct;6(10):803-12. doi: 10.1038/nrc1970.

  PMID: 16990857 BACKGROUND

• Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

  PMID: 20130576 BACKGROUND

• Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol. 1999 Aug;6(8):559-68. doi: 10.1016/s1074-5521(99)80088-x.

  PMID: 10421767 BACKGROUND

• Escuin-Ordinas H, Liu Y, Sun L, Hugo W, Dimatteo R, Huang RR, Krystofinski P, Azhdam A, Lee J, Comin-Anduix B, Cochran AJ, Lo RS, Segura T, Scumpia PO, Ribas A. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. PLoS One. 2021 Jun 23;16(6):e0252597. doi: 10.1371/journal.pone.0252597. eCollection 2021.

  PMID: 34161353 BACKGROUND

• Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, Cochran AJ, Modlin RL, Herschman HR, Lo RS, McBride WH, Segura T, Ribas A. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nat Commun. 2016 Aug 1;7:12348. doi: 10.1038/ncomms12348.

  PMID: 27476449 BACKGROUND

• Balmain A, Ramsden M, Bowden GT, Smith J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature. 1984 Feb 16-22;307(5952):658-60. doi: 10.1038/307658a0.

  PMID: 6694757 BACKGROUND

• Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, Baselga J. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 2001 Sep 1;61(17):6500-10.

  PMID: 11522647 BACKGROUND

MeSH Terms

Conditions

Varicose Ulcer

Condition Hierarchy (Ancestors)

Varicose Veins; Vascular Diseases; Cardiovascular Diseases; Leg Ulcer; Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Antoni Ribas, M.D., PhD

  University of California, Los Angeles

  STUDY DIRECTOR

• Steven Farley, M.D.

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

• Aksone Nouvong, MD

  University of California, Los Angeles

  STUDY CHAIR

• Jessica O'Conell, MD

  University of California, Los Angeles

  STUDY CHAIR

• Vincent Rowe, MD

  University of California, Los Angeles

  STUDY CHAIR

Central Study Contacts

Ignacio Baselga, PhD

CONTACT

3102063548; ibaselga@mednet.ucla.edu

Cynthia R Gonzalez

CONTACT

cynhtiargonzalez@mednet.ucla.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor of medicine, surgery, and molecular and medical pharmacology at UCLA

Study Record Dates

• First Submitted: March 5, 2026
• First Posted: March 11, 2026
• Study Start (Estimated): October 2, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): June 1, 2027
• Last Updated: May 29, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)